Ascentage Pharma Group International announced a clarification regarding its previously disclosed equity incentive plans. The company confirmed that the annual general meeting (AGM) at which shareholders approved the scheme mandate limits for the 2021 Restricted Share Unit (RSU) Scheme, the 2022 RSU Scheme, and the Post-IPO Share Option Scheme took place on 19 May 2025, not 20 May 2026 as earlier stated.

All other details in the 29 June 2026 announcement—covering additional grants of RSUs and options under the respective schemes—remain unchanged. The correction solely addresses the AGM date reference to ensure procedural accuracy for satisfying the newly granted awards and options.

The board composition is unchanged, led by Chairman and Executive Director Dr. Yang Dajun, alongside two non-executive directors and six independent non-executive directors. The company emphasised that this update should be read in conjunction with the original 29 June 2026 announcement, with no further amendments required.